Rosalia Moreddu is an Assistant Professor (called Lecturer in the UK) at the University of Southampton, UK, since November 2024.

Since May 2025, she leads the Biophysics Engineering Group, developing measurement technologies and biophysics platforms that use electrical and mechanical cues to interrogate and control cellular states, with applications spanning medicine and engineering.

She was previously a Marie Skłodowska-Curie Fellow on her EU project "COSMOS" at the Italian Institute of Technology, where she introduced the research lines of cancer bioelectronics and cell electromechanics, and co-developed non-invasive intracellular recording sensors. She obtained her PhD from the University of Birmingham/Imperial College London (UK) working on biosensing platforms for body fluid screening. Prior to her PhD, she worked as an Engineer at CERN (Switzerland) developing microfluidic technologies for particle detection. During her studies, she acquired research trainings in Switzerland, France, Taiwan, and the USA.

Since 2025, she founded the Bioelectricity Cluster organisation, serves as Associate Editor for Bioelectricity (Mary Ann Liebert), as expert reviewer for the Swiss National Science Foundation (SNSF), the European Commission (EC), the German Academy Exchange Service (DAAD) and the Linz Institute of Technology (LIT, Austria), and as external consultant for the John Templeton Foundation (USA) on multi-million investments at the engineering–life sciences intersection. At the University of Southampton, she was awarded a £180k MULSER equipment award from the Strategic Research and Infrastructure Panel, and a £110k funding from the EPSRC Strategic Themes Doctoral Landscape Award on cancer electromechanics.

She published over 25 papers in journals such as Advanced Intelligent Systems, Nano Letters, Advanced Science, Small, Nature Communications, and the ACS family, has delivered over 20 invited research talks internationally, is co-inventor of one patent, and was previously the founder of an Entrepreneur First–backed startup, Dromadis Health.